METamplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy
Author:
Affiliation:
1. State Key Laboratory of Oncology in South China; Guangzhou China
2. Department of Medical Oncology; Sun Yat-sen University Cancer Center; Guangzhou China
3. Department of Molecular Pathology; Sun Yat-sen University Cancer Center; Guangzhou China
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28454/fullpdf
Reference34 articles.
1. Patterns of cancer incidence, mortality, and prevalence across 5 continents: defining priorities to reduce cancer disparities in different geographic regions of the world;Kamangar;J Clin Oncol.,2006
2. Incidence and mortality of gastric cancer in China;Yang;World J Gastroenterol.,2006
3. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer;Pyrhonen;Br J Cancer.,1995
4. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group;Cutsem;J Clin Oncol.,2006
5. Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie;Al-Batran;J Clin Oncol.,2008
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Precision treatment paradigm: Genomic features and therapeutic implications in mesenchymal‐epithelial transition‐amplified gastric cancer;Clinical and Translational Discovery;2024-07-31
2. Advances in MET tyrosine kinase inhibitors in gastric cancer;Cancer Biology & Medicine;2024-05-10
3. MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities;Cancers;2023-01-18
4. Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors;Targeted Oncology;2022-12-02
5. MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer;Pathology and Oncology Research;2022-11-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3